ArticleCancer chemotherapy and pharmacology2025
Risk factors and prediction models for cardiotoxicity induced by anthracyclines in malignant chemotherapy.
Article in Cancer chemotherapy and pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate risk factors for cancer therapy-related cardiac dysfunction (CTRCD) in patients receiving anthracycline-based chemotherapy and develop a predictive model for assessing the risk of CTRCD. MATERIALS AND
methodsPatients with breast cancer or lymphoma who underwent chemotherapy were retrospectively enrolled. Independent risk factors were identified for CTRCD, and a clinical prediction model (nomogram) was constructed and evaluated.
results324 patients were randomly divided into the training and validation cohorts, and patients in the training cohort were further divided into the CTRCD positive (n = 48) and negative cohort (n = 222). Body mass index (BMI) ≥ 25, brain natriuretic peptide (BNP) acuity 52 pg/ml, pathologic stage, low density lipoprotein (LDL) or greater tendency for 3.37 / L, combined HER-2 class drugs, and cumulative dose of anthracycline of 550 mg /m2 were independent risk factors for CTRCD. The C-index of the CTRCD prediction map was 0.872 (95% confidence interval or CI: 0.821–0.923) in the training cohort, similar to that of 0.886 (95% CI: 0.799–0.974) in the validation cohort. The cut-off value of the receiver operating characteristics (ROC) curve analysis in the training cohort was 0.164. Good agreement was shown in the predicted data of the training group (P = 0.837) and the verification group (P = 0.700). The observed probability predicting CTRCD was close to the actual probability. The decision curve analysis (DCA) showed that the constructed nomogram had a high clinical application prospect.
conclusionBMI ≥ 25, history of diabetes, BNP ≥ 52 pg/ml, LDL ≥ 3.37 mmol/L, pathological stage, and cumulative anthracycline dose ≥ 550 mg/m² were independent risk factors for CTRCD. The nomogram model demonstrates excellent predictive accuracy, with a C-index of 0.872 in the training cohort and 0.886 in the validation cohort, offering a reliable tool for identifying high-risk for CTRCD.
Indexed as
Identifiers
40622424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.